# Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)

> **NCT01685008** · PHASE2 · COMPLETED · sponsor: **MorphoSys AG** · enrollment: 92 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** MOR00208 (formerly Xmab 5574)

## Key facts

- **NCT ID:** NCT01685008
- **Lead sponsor:** MorphoSys AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-23
- **Primary completion:** 2022-04-06
- **Final completion:** 2022-04-06
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01685008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01685008, "Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01685008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*